Neurotrope, Inc., to Present at Noble Financial Tenth Annual Equity Conference in Sandpiper Bay, Florida
PLANTATION, Fla., Jan. 14, 2014 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that Dr. James New, the Company’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ Tenth Annual Equity Conference 11:00AM Eastern Time on Tuesday, January 21, 2014 at the Club Med Resort in Sandpiper Bay, Florida.
The Company will discuss its unique position as it works towards commercializing certain technologies that were initially developed by the Blanchette Rockefeller Neurosciences Institute and its affiliates, for the diagnosis of and treatment of Alzheimer’s Disease. The Company’s core research program is targeted towards developing novel therapeutic modalities to treat a variety of neurodegenerative pathologies. Details of the Company’s initiatives for 2014 will also be provided.
Neurotrope, Inc. will webcast its corporate presentation at:
The webcast may also be accessed on the Company’s website, www.neurotropebioscience.com. The webcast can be accessed live and will be available for replay after the presentation on the Company’s website.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a minimally-invasive diagnostic test for Alzheimer’s Disease and a drug candidate called bryostatin for the treatment of Alzheimer’s Disease, both of which are in the clinical testing stage. These technologies were initially developed by Blanchette Rockefeller Neurosciences Institute (“BRNI”) and its affiliates starting in 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer’s Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer’s Disease, the Company currently intends to pursue the development of bryostatin analogues, which have demonstrated preclinical potency in treating ischemic stroke and other neurodegenerative disorders.
Please visit www.neurotropebioscience.com for further information.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of commercially viable pharmaceuticals, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including, the Company’s current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
For additional information, please contact:
SOURCE Neurotrope, Inc.